ArticleNature medicine2023

Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial.

Byoung Chul Cho et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.